All Stories

  1. The clinical antiprotozoal drug halofuginone promotes weight loss by elevating GDF15 and FGF21
  2. Advances in, and prospects of, 3D preclinical models for skin drug discovery
  3. Smad transcription factors as mediators of 7 transmembrane G protein-coupled receptor signalling
  4. Response to retention hypothesis as a source of targets for arterial wall-directed therapies to prevent atherosclerosis: A critical review
  5. Mechanistic insight: Linking cardiovascular complications of inflammatory bowel disease
  6. Transforming growth factor-β receptors: versatile mechanisms of ligand activation
  7. Gαq Is the Specific Mediator of PAR-1 Transactivation of Kinase Receptors in Vascular Smooth Muscle Cells
  8. Non-Mouse Models of Atherosclerosis: Approaches to Exploring the Translational Potential of New Therapies
  9. Endothelin‐1 dependent expression of GAG genes involves NOX and p38 mediated Smad linker region phosphorylation
  10. Influence of PEGylated porous silicon nanoparticles on permeation and efflux of an orally administered antibiotic
  11. Lipopolysaccharide acting via toll-like receptor 4 transactivates the TGF-β receptor in vascular smooth muscle cells
  12. Endothelin-1 mediated glycosaminoglycan synthesizing gene expression involves NOX-dependent transactivation of the transforming growth factor-β receptor
  13. Akt acts as a switch for GPCR transactivation of the TGF‐β receptor type 1
  14. Lipopolysaccharide Acting Via Toll Like Receptor 4 Transactivates The TGF-β Receptor in Vascular Smooth Muscle cells
  15. YY‐11, a camel milk‐derived peptide, inhibits TGF‐β‐mediated atherogenic signaling in human vascular smooth muscle cells
  16. Endothelial Dysfunction and Cardiovascular Disease: History and Analysis of the Clinical Utility of the Relationship
  17. Curcumin Inhibits Lysophosphatidic Acid Mediated MCP-1 Expression via Blocking ROCK Signalling
  18. Targeted Molecular Imaging of Cardiovascular Diseases by Iron Oxide Nanoparticles
  19. Lysophosphatidic acid receptor 5 transactivation of TGFBR1 stimulates the mRNA expression of proteoglycan synthesizing genes XYLT1 and CHST3
  20. Artemisinin inhibits glycosaminoglycan chain synthesizing gene expression but not proliferation of human vascular smooth muscle cells
  21. Smad2 linker region phosphorylation is an autonomous cell signalling pathway: Implications for multiple disease pathologies
  22. Toll-like Receptor 4 Stimulates Gene Expression via Smad2 Linker Region Phosphorylation in Vascular Smooth Muscle Cells
  23. The Role of Toll-like Receptors in Atherothrombotic Cardiovascular Disease
  24. ROS directly activates transforming growth factor β type 1 receptor signalling in human vascular smooth muscle cells
  25. Lysophosphatidic acid and its receptors: pharmacology and therapeutic potential in atherosclerosis and vascular disease
  26. GPCR transactivation signalling in vascular smooth muscle cells: role of NADPH oxidases and reactive oxygen species
  27. Smad linker region phosphorylation is a signalling pathway in its own right and not only a modulator of canonical TGF-β signalling
  28. Mechanisms of PAR-1 mediated kinase receptor transactivation: Smad linker region phosphorylation
  29. Treatment of atherosclerotic plaque: perspectives on theranostics
  30. Individual Smad2 linker region phosphorylation sites determine the expression of proteoglycan and glycosaminoglycan synthesizing genes
  31. Endothelial function and dysfunction: Impact of metformin
  32. Transforming growth factor–β1 mediated CHST11 and CHSY1 mRNA expression is ROS dependent in vascular smooth muscle cells
  33. Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics
  34. Thrombin promotes PAI-1 expression and migration in keratinocytes via ERK dependent Smad linker region phosphorylation
  35. Signalling pathways regulating galactosaminoglycan synthesis and structure in vascular smooth muscle: Implications for lipoprotein binding and atherosclerosis
  36. G protein coupled receptors can transduce signals through carboxy terminal and linker region phosphorylation of Smad transcription factors
  37. Flavopiridol Inhibits TGF-β-Stimulated Biglycan Synthesis by Blocking Linker Region Phosphorylation and Nuclear Translocation of Smad2
  38. Activatable magnetic resonance nanosensor as a potential imaging agent for detecting and discriminating thrombosis
  39. RNA sequencing to determine the contribution of kinase receptor transactivation to G protein coupled receptor signalling in vascular smooth muscle cells
  40. Animal models for assessing the impact of natural products on the aetiology and metabolic pathophysiology of Type 2 diabetes
  41. Insights into cellular signalling by G protein coupled receptor transactivation of cell surface protein kinase receptors
  42. Endothelin-1 (ET-1) stimulates carboxy terminal Smad2 phosphorylation in vascular endothelial cells by a mechanism dependent on ET receptors andde novoprotein synthesis
  43. Gaq proteins: molecular pharmacology and therapeutic potential
  44. The role of specific Smad linker region phosphorylation in TGF-β mediated expression of glycosaminoglycan synthesizing enzymes in vascular smooth muscle
  45. Evaluation of the potential synergism of imatinib-related poly kinase inhibitors using growth factor stimulated proteoglycan synthesis as a model response
  46. Integrating the GPCR transactivation-dependent and biased signalling paradigms in the context of PAR1 signalling
  47. Multiple Growth Factors, But Not VEGF, Stimulate Glycosaminoglycan Hyperelongation in Retinal Choroidal Endothelial Cells
  48. Protease activated receptor-1 mediated dual kinase receptor transactivation stimulates the expression of glycosaminoglycan synthesizing genes
  49. Structure, Function, Pharmacology, and Therapeutic Potential of the G Protein, Gα/q,11
  50. Peptidyl-prolyl isomerases: Functionality and potential therapeutic targets in cardiovascular disease
  51. The expansion of GPCR transactivation-dependent signalling to include serine/threonine kinase receptors represents a new cell signalling frontier
  52. 25Years of endothelin research: the next generation
  53. Transforming growth factor β-mediated site-specific Smad linker region phosphorylation in vascular endothelial cells
  54. Assessing the Role of Gαq/11 in Cellular Responses: An Analysis of Investigative Tools
  55. Atherogenic, fibrotic and glucose utilising actions of glucokinase activators on vascular endothelium and smooth muscle
  56. Assessing the Role of Gαq/11 in Cellular Responses: An Analysis of Investigative Tools
  57. Transforming growth factor-β signalling: Role and consequences of Smad linker region phosphorylation
  58. Suramin inhibits PDGF-stimulated receptor phosphorylation, proteoglycan synthesis and glycosaminoglycan hyperelongation in human vascular smooth muscle cells
  59. (S)-[6]-Gingerol inhibits TGF-β-stimulated biglycan synthesis but not glycosaminoglycan hyperelongation in human vascular smooth muscle cells
  60. Therapeutic implications of endothelin and thrombin G-protein-coupled receptor transactivation of tyrosine and serine/threonine kinase cell surface receptors
  61. Cell biology of Smad2/3 linker region phosphorylation in vascular smooth muscle